Evidence map›Paper›PMID 37773092›Full record

Observational studyThe journal of headache and pain2023

COVID-19 vaccination-related headache showed two different clusters in the long-term course: a prospective multicenter follow-up study (COVA-Head Study).

Arife Çimen Atalar, Ayşe Nur Özdağ Acarlı, Betül Baykan, Paolo Martelletti, Hayrunnisa Bolay, Mustafa Ertaş, Esme Ekizoğlu, Ömer Karadaş, Burcu Polat, Işıl Yazıcı Gençdal and 11 more

Open access · goldAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in The journal of headache and pain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 5 countries.

Arife Çimen AtalarDepartment of Neurology, Health Sciences University, Kanuni Sultan Süleyman Education and Research Hospital, Istanbul, Turkey. cimenatalar@gmail.com.ORCID http://orcid.org/0000-0003-0328-9607
Ayşe Nur Özdağ AcarlıDepartment of Neurology, Ermenek State Hospital, Karaman, Turkey.
Betül BaykanDepartment of Neurology, Headache Center, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
Paolo MartellettiDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Hayrunnisa BolayMedical Faculty, Department of Neurology and Algology, Gazi University, Ankara, Turkey.
Mustafa ErtaşDepartment of Neurology, Headache Center, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
Esme EkizoğluDepartment of Neurology, Headache Center, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
Ömer KaradaşDepartment of Neurology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Burcu PolatSchool of Medicine, Department of Neurology, Istanbul Medipol University, Istanbul, Turkey.
Işıl Yazıcı GençdalBakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic and Neurosurgical Diseases, University of Health Sciences, Istanbul, Turkey.
David Garcia AzorinDepartment of Neurology, Hospital Clínico Universitario de Valladolid, Headache Unit, Valladolid, Spain.
Dimos MitsikostasFirst Neurology Department, Medical School, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Loukia ApostolakopoulouFirst Neurology Department, Medical School, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Hamit GençUniversity of Health Sciences, Van Training and Research Hospital, Van, Türkiye.
Pınar Yalınay DikmenSchool of Medicine, Department of Neurology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
Esra Acıman DemirelBülent Ecevit University Neurology Department, Zonguldak, Turkey.
Elif Ilgaz AydınlarSchool of Medicine, Department of Neurology, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
Rabia Gökçen Gözübatık-CelikBakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic and Neurosurgical Diseases, University of Health Sciences, Istanbul, Turkey.
Javid ShafiyevDepartment of Neurology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Bahar TaşdelenDepartment of Biostatistics and Medical Informatic, Mersin University School of Medicine, Mersin, Turkey.
Aynur ÖzgeMedical Faculty, Department of Neurology, Mersin University, Mersin, Türkiye.
Sağlık Bilimleri Üniversitesi · TRIstanbul University · TRBakırköy Psychiatric Hospital · TRKent Hastanesi · TRMersin Üniversitesi · TRNational and Kapodistrian University of Athens · GRBülent Ecevit University · TRGazi University · TRHospital Clínico Universitario de Valladolid · ESIstanbul Medipol University · TRSapienza University of Rome · ITSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough acute headache following COVID-19 vaccination is widely acknowledged, the long-term progression of these headaches remains poorly understood. Our objective was to identify various phenotypes of prolonged or worsened headaches associated with COVID-19 vaccination and document any changes in these phenotypes over an extended period. Additionally, we aimed to document the diverse headache presentations among patients with pre-existing primary headaches.

methodsA multinational, prospective observational study was conducted to investigate prolonged or worsened headaches associated with COVID-19 vaccination. Questionnaires assessing COVID-19 vaccination-related headaches at three time points (initial visit, 3

resultsAmong the 174 patients included in the study, there was a female-to-male ratio of 128 (73.6%) to 46 (26.4%). The mean age of the patient group was 45.2 ± 13.3 years, and 107 patients (61.5%) had a pre-existing history of primary headaches. Through the analysis, two major clusters were identified based on headache characteristics at each visit. During the first visit (n = 174), Cluster 1 primarily comprised patients with a history of primary headaches, frontal localization of pain, throbbing pain type, more severe headaches accompanied by symptoms such as nausea, phonophobia, photophobia, and osmophobia, and worsened by physical activity. In contrast, Cluster 2 consisted of patients with longer headache durations (over one month) and a stabbing/pressing quality of pain. Patients in Cluster 1 had a higher prevalence of migraine as the pre-existing primary headache disorder compared to Cluster 2 (90.48% vs. 68.18%, respectively; p = 0.005).

conclusionThe identification of two distinct phenotypes of prolonged or worsened headaches related to COVID-19 vaccination can provide valuable clinical insights. Having an awareness of the potential worsening of headaches following COVID-19 vaccination, particularly in patients with a primary headache disorder such as migraine, can help clinicians and headache experts anticipate and adjust their treatment strategies accordingly. This knowledge can aid in preplanning treatment modifications and optimize patient care.

Indexed as

COVID-19Migraine DisordersAdultCOVID-19 VaccinesFemaleFollow-Up StudiesHeadacheHumansMaleMiddle AgedProspective StudiesCOVID-19 VaccinesCOVIDHeadacheLong-COVIDPrimary headacheVaccination

Identifiers

PMID37773092
PMCPMC10541695
OpenAlexW4387157231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.